This article covers US GAAP, where the general rule under ASC 730 is to expense qualifying R&D costs as incurred. But the rule has real boundaries. Certain assets, software projects, acquired technology, and funding arrangements fall under different guidance entirely.
Here's what we'll walk through: what actually counts as R&D, how common cost categories get treated, when capitalization becomes an option, what documentation auditors expect, and how the book treatment diverges from tax rules.
Key Takeaways
- Qualifying R&D costs under ASC 730 are expensed as incurred, not capitalized by default
- Alternative future use, activity type, and other GAAP guidance all factor into the classification
- Internal-use software, software for sale, acquired in-process R&D, and grants each follow separate rules
- Project-level records and documented judgment calls are what auditors actually look for
What Is Research and Development in Accounting?
ASC 730 defines research as planned search or critical investigation aimed at discovering new knowledge. That knowledge may lead to a new or improved product or process.
Development takes the knowledge from research and turns it into a design for a new offering or a significant improvement to an existing one, before commercial production begins.
In practice, this covers:
- Laboratory investigation into new materials or formulations
- Prototype design and engineering experimentation
- Clinical development work ahead of regulatory approval
- Building new software functionality that doesn't yet exist
Here's the catch many teams miss: an activity can feel innovative from a business standpoint without qualifying as R&D for financial reporting purposes. Classification depends on the accounting guidance and the actual substance of the work, not the department label stamped on the project.
Activities That Don't Qualify
ASC 730-10-55 draws some clear lines. The following generally fall outside R&D:
- Routine quality control during commercial production
- Troubleshooting breakdowns on an existing production line
- Periodic or routine product alterations
- Customer-specific modifications to an existing product
- Market research or market testing
- General administrative or selling-function work
A pilot plant testing a new process at below-commercial scale is R&D. That same plant, once it's producing at commercially viable volumes, is a fixed asset running under ordinary production accounting. The shift happens at the point of commercial viability, not at some arbitrary project milestone.
Accounting for R&D Under US GAAP
ASC 730-10-25-1 is direct: in-scope R&D costs get charged to expense when incurred. Capitalizing internally generated R&D isn't a policy election a company can choose because management expects future benefits. There's no "we're confident this will pay off" exception.
Why the Expense Model Exists
The reasoning traces back to FASB's Statement No. 2 from 1974, which pointed to the uncertainty around individual projects' future benefits and the difficulty of reliably measuring anticipated returns on R&D spending. That logic still underpins FASB's Statement No. 2 today, even though the operative rule now sits in ASC 730.
"As incurred" is a specific trigger, worth getting right:
- It refers to when goods or services are received, not when the invoice gets paid
- Accrued R&D costs belong in the current period if services were performed but billing is incomplete
- A nonrefundable advance paid to a contract research organization is capitalized as a prepaid asset first, then expensed as the services are actually delivered
That last point trips up a lot of companies. The advance payment itself isn't R&D expense. It only becomes expense as the CRO performs the work.
The Financial Statement Effect
Because qualifying costs hit the income statement immediately, companies don't carry an internally generated R&D intangible asset under the basic ASC 730 model. Operating income absorbs the cost in the period incurred, full stop.
US GAAP versus IFRS: both frameworks expense research. They diverge on development spending:
- IFRS (IAS 38): Capitalize qualifying development costs once six criteria are met, including technical feasibility and probable future economic benefits
- US GAAP (ASC 730): No equivalent development-capitalization test
Companies reporting under both frameworks should treat this as a genuine point of divergence. Get specialist review before assuming one framework's conclusion applies to the other.
Which R&D Costs Qualify, and What Are the Exceptions?
Most direct project costs are straightforward. Costs that get included in R&D expense include:
- Employee compensation for engineers running experiments
- Contractor fees, lab and testing costs, and clinical trial expenses
- Prototype materials and supplies tied to a qualifying project
The harder questions show up at the edges.
Materials, Equipment, and Alternative Future Use
ASC 730-10-25-2(a) allows capitalization of materials, equipment, and facilities, but only when they have alternative future use in other R&D projects or elsewhere in the business. Research-only items without that alternative use get expensed outright. Equipment that can genuinely serve future projects follows standard property, plant, and equipment guidance, with its R&D-related depreciation flowing into R&D expense.
Here's where companies get it wrong: a pharmaceutical compound that might treat other diseases down the road doesn't have alternative future use today if that potential depends entirely on the current trial succeeding. KPMG's R&D handbook makes this distinction explicit: alternative use has to be supportable at acquisition, not contingent on a future outcome.
Indirect Costs
Shared facilities, utilities, depreciation on shared assets, and support function costs can be allocated to R&D. The allocation methodology needs to be reasonable, applied consistently, and limited to costs clearly tied to R&D activity. General administrative overhead that doesn't connect to R&D stays out.
Software Requires Careful Scoping
Software cost treatment depends entirely on what the software is for:
| Software Purpose | Governing Model | Key Trigger |
|---|---|---|
| Internal-use software | ASC 350-40 | Capitalize qualifying development costs; expense training and maintenance |
| Software sold or licensed | ASC 985-20 | Expense as R&D until technological feasibility; capitalize after |
| Software used in R&D itself | Treated as R&D | Internal development expensed; purchased software may qualify for alternative-use capitalization |
Note that ASU 2025-06 replaces the old prescribed stages for internal-use software with a management-authorization and probable-to-complete threshold, effective for annual periods beginning after December 15, 2027. Companies adopting early should flag that in their policy documentation.
Acquired In-Process R&D
In a business combination, acquired IPR&D gets recognized at fair value as an indefinite-lived intangible asset, regardless of alternative future use. It is tested for impairment annually until the project completes or gets abandoned.
In an asset acquisition, the amount allocated to IPR&D without alternative future use is expensed immediately instead. Acquiring IPR&D in either structure doesn't create a path to capitalize subsequent internal R&D spending on that same project.
Grants and Collaborative Arrangements
Under ASC 808, collaborative arrangements require active participation and exposure to risk and reward on both sides. A party that's purely funding the work generally doesn't qualify as a collaborator.
Depending on the contract, receipts might be:
- Revenue under ASC 606
- A reduction to R&D expense
- A liability if the funding is repayable regardless of research outcome
Don't assume every grant or reimbursement automatically nets against R&D expense; the contract terms determine the answer.
How to Record and Support R&D Costs: A Practical Finance-Team Process
Correct classification on paper still fails audit scrutiny without supporting process and documentation. Here's a five-step framework finance teams can use.
- Build a project inventory. List each R&D program with its objective, responsible team, development stage, expected output, and the accounting guidance that potentially applies. This becomes your reference point for every later judgment call.
- Map costs to projects. Tie payroll, purchase orders, invoices, contractor billings, and shared costs to the correct project using a documented allocation methodology. Unsupported estimates are one of the fastest ways to draw audit questions.
- Review boundary costs separately. Software, equipment, prototypes, patents, facilities, regulatory activities, grants, and acquired intellectual property each need separate evaluation, since they don't follow the basic ASC 730 expense rule.
- Establish period-end procedures. Accrue unbilled R&D services, reconcile project-level records to the general ledger, and document significant judgments made during close.
- Maintain an accounting memo. Keep a written record supporting the R&D definition applied, how exceptions were handled, the alternative-future-use assessment, and management's sign-off.
Smaller finance teams often have the technical knowledge but not the bandwidth to build this documentation while also closing the books.
Firms like Stratum Advisory Partners, LLC often support that gap with scoped technical accounting analysis, supporting documentation, or senior expertise during an audit, a transaction, or a complex accounting question internal staff cannot fully resolve.
Financial Statement Presentation, Disclosures, and Tax Considerations
R&D expense is typically presented as a separate line within operating expenses on the income statement, though the exact placement depends on the company's chart of accounts, industry, and materiality. Amgen's financial statements, for example, show R&D separately from cost of sales under operating expenses, a common pattern among research-intensive companies.
Is R&D Part of COGS?
Generally, no. R&D is an operating expense, not cost of goods sold. That said, classification still depends on the nature of specific costs and a company's own presentation policy, so this isn't an absolute rule written into the codification.
Disclosure Expectations
Public companies and other reporting entities should be ready to address:
- Total R&D expense for each period presented
- Material changes in spending and what drove them
- Significant accounting policies around expensing versus capitalization
- Material judgments, including alternative-use conclusions
- Funding arrangements and how they're presented
SEC staff regularly ask for more granular breakdowns, whether by product line, internal versus external spend, or expense nature, so documentation supporting the disclosed figures matters as much as the figures themselves.
Book Versus Tax: Keep Them Separate
Tax treatment of R&D costs runs on its own track entirely. Under current federal rules:
- Domestic research expenditures for tax years beginning after December 31, 2024 are generally deductible under Section 174A, with an option to capitalize and amortize over not less than 60 months
- Foreign research expenditures still require capitalization and 15-year amortization
IRS guidance also addresses transition elections for unamortized amounts from the 2022 through 2024 tax years, when mandatory five-year domestic amortization applied.
None of this changes the GAAP conclusion. Tax capitalization rules don't authorize book capitalization, and the two analyses should be documented independently. Accounting standards, tax law, and SEC expectations shift often enough that R&D classification should be revisited periodically rather than assumed to carry forward from last year.
Frequently Asked Questions
Should R&D be capitalized or expensed in accounting?
Qualifying R&D under US GAAP is generally expensed as incurred under ASC 730. Certain assets, software costs, acquisitions, and specific exceptions require separate analysis before you can conclude on treatment.
How are research and development costs treated in accounting?
ASC 730 requires expensing as costs are incurred, including accrued costs for services performed but not yet billed. Companies still need to evaluate classification boundaries and other applicable GAAP guidance for exceptions.
Is R&D included in COGS?
R&D is generally presented as an operating expense rather than cost of goods sold. The specific classification depends on the nature of the activity and the company's own accounting and presentation policies.
Can you give me an example of an R&D expense?
Common examples include compensation for engineers running experiments, prototype testing costs, clinical research expenses, and laboratory supplies tied to a qualifying project. Each needs to connect to a genuine research or development activity.
What is research and development in accounting?
Research is planned investigation aimed at discovering new knowledge; development applies that knowledge to design a new or improved product, process, or system. Identifying which activity you're looking at is the first step toward the right accounting treatment.
